Carregant...
Cell line access to revolutionize the biosimilars market
Biologic drugs are notoriously expensive. Biosimilars, though priced lower, are also costly. Analysis of the cost of production of biologics suggests that the cost of manufacture is in many cases less than 10% of the price in high-income countries, and less than a third of the price of biosimilars i...
Guardat en:
| Publicat a: | F1000Res |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
F1000 Research Limited
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6051195/ https://ncbi.nlm.nih.gov/pubmed/30057752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.14808.1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|